BioSpace News Archive

Boston Pharmaceuticals announced it will present new data supporting its long-acting dosing schedule and an analysis of treatment in diabetic sub-groups from the Phase 2a Part A clinical program evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis, at the American Association for the Study of Liver Diseases The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Discovery Life Sciences, the Biospecimen and Biomarker Specialists, announced the appointment of Greg Herrema as its new chief executive officer.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from the Phase 2a IRIS-RA clinical study for the treatment of adults living with moderate to severe active rheumatoid arthritis who have tested positive for anti-citrullinated protein antibodies a and/or rheumatoid factor, and who have had an inadequate response or intolerance to at least one anti-tumor necrosis factor therapy.

Immunovia, the diagnostics company focused on early detection of pancreatic cancer, announced the successful completion of the discovery phase for the Company’s next-generation test.

InspectIR Systems, a medical technology company focused on point-of-care diagnostics, today announced the successful completion of its Phase I study evaluating the performance of the company’s point-of-care breathalyzer technology for identifying Dengue Fever and Chikungunya.

Takeda announced that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 inhibitor with next generation selectivity, in patients with active psoriatic arthritis.

Calliditas Therapeutics AB announced that management will present at and participate in the following conferences.

Aurinia Pharmaceuticals Inc., announced the presentation of five studies at the annual American College of Rheumatology Convergence 2023 taking place in San Diego, CA, November 10-15.

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”) is pleased to announce the approval of Health Canada’s Pest Management Regulatory Agency (“PMRA”) to commence large-scale field trials via NexusBioAg’s 2024 BioAdvantage

Enable Injections, Inc., a company developing and manufacturing the enFuse® platform of wearable drug delivery systems, is pleased to announce the appointment of Vickie Capps to the company’s Board of Directors as the head of the audit committee.